Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
Condition: Drug-drug Interaction; Autoimmune Diseases; Fibrotic Disease
MeSH terms: Autoimmune Diseases
Intervention: Belumosudil; Itraconazole; Rabeprazole; Rifampicin; Omeprazole
Intervention description: Development candidate; Perpetrator drug; Perpetrator drug; Perpetrator drug; Perpetrator drug
Intervention MeSH terms: Itraconazole; Rifampin; Omeprazole; Rabeprazole; Belumosudil
Phase: Phase 1
Study type: Interventional
Primary purpose: Basic Science
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Intervention model description: Two-Part, Non-Randomised
Masking: None (Open Label)
Enrollment: 73.0
Sex: Male
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This is a single-center, 2-part, non-randomized, open-label study of the drug-drug
      interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and
      omeprazole in healthy male subjects.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Healthy males

          2. Age 18 to 55 years

          3. Good state of health (mentally and physically) as indicated by a comprehensive
             clinical assessment (detailed medical history and a complete physical examination),
             electrocardiogram (ECG) and laboratory investigations (hematology, clinical chemistry,
             and urinalysis)

          4. Body weight ≥50 kg

          5. Body mass index of 18.0 to 32.0 kg/m^2 or, if outside the range, considered not
             clinically significant by the investigator

          6. Must be willing and able to communicate and participate in the whole study

          7. Must provide written informed consent

          8. Must adhere to the contraception requirements

        Exclusion Criteria:

          1. Subjects who had previously participated in any other investigational study drug trial
             in which receipt of an IP occurred within 90 days prior to dosing. (Subjects who had
             previously received belumosudil in Part 1 at least 90 days prior to dosing in Part 2
             were eligible to participate.)

          2. Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          3. Subjects with pregnant partners

          4. History of any drug or alcohol abuse in the past 2 years

          5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25
             mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)

          6. Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening and admission

          7. Current users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 12 months

          8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as
             assessed by the investigator at screening

          9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator

         10. Positive drugs of abuse test result at screening and admission

         11. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

         12. Evidence of renal impairment at screening, as indicated by an estimated creatinine
             clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation

         13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or gastrointestinal disease, neurological or psychiatric disorder, as judged by the
             investigator

         14. Subject has a history or presence of any of the following:

               -  Active gastrointestinal disease requiring therapy

               -  Hepatic disease and/or alanine aminotransaminase (ALT) or aspartate
                  aminotransaminase (AST) > ULN

               -  Renal disease and/or serum creatinine > ULN

               -  Other condition known to interfere with the absorption, distribution, metabolism
                  or excretion of drugs

         15. Subjects with a history of cholecystectomy or gall stones

         16. Subject has QT interval corrected using Fridericia's formula (QTcF) intervals >450
             msec at screening or admission

         17. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients; including intolerance to itraconazole, rabeprazole, and rifampicin

         18. Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hayfever is allowed unless it is active

         19. Donation or loss of greater than 400 mL of blood within the previous 3 months

         20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other
             than 4 g per day paracetamol) or herbal remedies in the 14 days before IP
             administration.

         21. Failure to satisfy the investigator of fitness to participate for any other reason

        Subjects Agreed to the Following Restrictions During the Duration of the Study:

          1. No alcohol during the 24-hour period prior to screening and the 24-hour period prior
             to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1,
             Periods 2 to 4 and Part 2, Period 2, until discharge for each treatment period.

          2. No food or drinks containing grapefruit or cranberry from 24 hours prior to admission
             in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1 Periods 2 to
             4 and Part 2 Period 2, until discharge for each treatment period.

          3. No food or drinks containing caffeine or other xanthines from 24 hours prior to
             admission until discharge for each treatment period.

          4. No food containing poppy seeds for 48 hours prior to screening and for 24 hours prior
             to admission until discharge for each treatment period.

          5. No unaccustomed or strenuous exercise from the 72-hour period before the screening
             visit and then from 24 hours prior to admission until discharge for each treatment
             period.